Eutelsat Communications (E3B)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 1.843 |
|---|---|
| 52-week range | 1.360 – 4.548 |
| Return, 1 month / 3 months | +4.6% / −14.1% |
| Return, 1 year / 3 years | −45.5% / −59.1% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 77.7% |
| Worst drawdown (1 year) | -69.6% |
| Average daily value traded | 0.14M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Eutelsat Communications is a satellite communications operator based in France. It owns and operates a fleet of satellites that carry television broadcasts, video feeds and data connections for broadcasters, telecom operators, businesses and government customers across Europe, Africa, the Middle East and other regions. The company also provides broadband and connectivity services, including satellite internet access, and supplies capacity to media and network partners.
The shares are listed on the XETRA Stock Exchange in Germany under the code E3B, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in one calendar year. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Eutelsat Communications (E3B) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 1.843 on 22 October 2026.
Its price-based Market X-Ray is 17 out of 100 (a weak price profile), ranking 644 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 45.5% and over the last three months it fell 14.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 11 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -19.7% | ||
| From 52-week high | -59.0% | ||
| Momentum | 13 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.1% | ||
| 6-month return | -36.9% | ||
| 12-month return, skipping the last month | -47.9% | ||
| Stability (higher is calmer) | 7 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 77.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -69.6% | ||
| Liquidity | 49 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.14M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +22.0% |
|---|---|
| 1 month | +4.6% |
| 3 months | −14.1% |
| 6 months | −36.9% |
| 1 year | −45.5% |
| 3 years | −59.1% |
| 5 years | −92.9% |
Signals
| 50-day / 200-day average | 1.761 / 2.294 |
|---|---|
| Golden / death cross (60 days) | Death, 54 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.120 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Nov 2022 | EUR 0.7259 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.